Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1991-12-17
1993-03-09
Schenkman, Leonard
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514863, A61K 3140
Patent
active
051927900
ABSTRACT:
This invention relates to the use of certain 3-substituted-2-oxindole derivatives to inhibit interleukin-1 biosynthesis in a mammal. This invention also relates to the use of such compounds for treating interleukin-1 mediated disorders and dysfunctions such as bone and connective tissue metabolism disorders and immune dysfunction in a mammal. The methods of this invention comprise administering an interleukin-1 biosynthesis inhibiting amount of the compounds and salts of this invention to such a mammal.
REFERENCES:
patent: 4556672 (1985-12-01), Kadin
patent: 4569942 (1986-02-01), Kadin
patent: 4677132 (1987-06-01), Hayward
patent: 4678802 (1987-07-01), Kadin
patent: 4725616 (1988-02-01), Kadin
patent: 4861794 (1989-08-01), Otterness
patent: 5047554 (1991-09-01), Ehrgott et al.
Etienne, A., et al., Int. J. Tissue Reac. 7:459-462 (1985).
Murota, S. et al., Drugs Exptl. Clin. Res. 11:641-644 (1985).
Kragballe, K. et al., Arch Dermatol. 119:548-552 (1983).
Meghji, S. et al., Calcif. Tissue Int. 41 (Supplement 2):16 (1987).
Offenbacher, S. et al., J. Dent. Res. 67:244 (1988).
Fogh, K. et al., Arch. Dermatol. Res. 280:430-436 (1988).
Kunkel, S. L. et al., "Arachidonic Acid Metabolites Regulate Interleukin-1 Production", Biochemical and Biophysical Res. Comm. 128:892-897 (1985).
Smith, R. J. et al., "Human Neutrophil Activation with Interleukin-1", Biochemical Pharmacology 36:3851-3858 (1987).
Hayward, M. et al., "Mechanisms of bone loss: rheumatoid arthritis, periodontal disease and osteoporosis", Agents and Actions 22:251-254 (1987).
Hayward, M. et al., Annual Reports in Medicinal Chemistry 22, Sect. IV, Chapter 17, pp. 172-177 (1987).
Dinarello, C. A., "An Update on Human Interleukin-1: From Molecular Biology to Clinical Relevance", J. Clin. Immunol., 5:287-297 (1985).
Camp, R. D. et al., "Psoriatic Skin Lesions Contain Biologically Active Amounts of an Interleukin 1-Like Compound", J. Immunol., 137:3469-3474 (1986).
Dinarello, C. A., "Biology of Interleukin 1", FASEB J. 2, 108-115 (1988).
Dinarello, C. A. et al., "The Influence of Lipoxygenase Inhibitors on the In Vitro Production of Human Leukocytic Pyrogen and Lymphocyte Activiating Factor (Interleukin-1)", Int. J. Immunopharmac., 6:43-50 (1984).
Dinarello, C. A. et al., "Role of Arachidonate Metabolism in the Immunoregulatory Function of Human Leukocytic Pyrogen/Lymphocyte-Activating Factor/Interleukin 1", J. Immunol., 130:890-895 (1983).
Meikle; M. C. et al., Chem. Abstracts 105:169829z.
McDonald, B. et al., "The Influence of a Novel Arachidonate Inhibitor, CP-66,248 on the Production and Activity of Human Monocyte IL-1", Arthritis Rheum. 32 (4 Suppl.):S17 (1988).
Otterness, I. G. et al., "Effects of CP-66,248 on IL-1 Synthesis of Murine Peritoneal Macrophages", Arthritis Rheum. 34 (4 Suppl.):S90 Abstract C55 (1988).
Goddard Carl J.
Hanson Douglas C.
Schulte Gary R.
Benson Gregg C.
Lumb J. Trevor
Pfizer Inc.
Richardson Peter C.
Schenkman Leonard
LandOfFree
3-substituted-2-oxindole derivatives as inhibitors of interleuki does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-substituted-2-oxindole derivatives as inhibitors of interleuki, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-substituted-2-oxindole derivatives as inhibitors of interleuki will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-211847